氢溴酸加兰他敏(Galantamine Hydrobromide) - 药物靶点：AChE_在研适应症：阿尔茨海默症_专利_临床

概要

基本信息

药物类型

小分子化药

别名

(-)-Galanthamine、Galantamine、Galantamine hydrobromide (JAN/USP)

+ [19]

靶点

AChE

作用机制

AChE抑制剂(乙酰胆碱酯酶抑制剂)

治疗领域

神经系统疾病

在研适应症

阿尔茨海默症

非在研适应症

认知障碍认知功能障碍血管性痴呆+ [8]

原研机构

Janssen Pharmaceuticals, Inc.

在研机构

Janssen Pharmaceuticals, Inc.Hikma Pharmaceuticals USA, Inc.Janssen, Inc.

+ [1]

非在研机构

Janssen Research & Development LLC

西安杨森制药有限公司

Janssen-Cilag SpA

+ [7]

最高研发阶段批准上市

首次获批日期

美国 (2001-02-28),

阿尔茨海默症痴呆

最高研发阶段(中国)批准上市

特殊审评-

登录后查看首次获批时间轴

结构

分子式C17H22BrNO3

InChIKeyQORVDGQLPPAFRS-XPSHAMGMSA-N

CAS号1953-04-4

关联

126

项与氢溴酸加兰他敏相关的临床试验

CTR20242087 / Active, not recruitingN/A

氢溴酸加兰他敏口崩片（8mg）在中国健康受试者中空腹和餐后给药条件下随机、开放、单剂量、两序列、两周期、双交叉生物等效性试验

按有关生物等效性试验的规定，选择ヤンセンファーマ株式会社持证的氢溴酸加兰他敏口腔崩解片（商品名：Reminyl®，规格：8mg）为参比制剂，对北京星昊医药股份有限公司生产并提供的受试制剂氢溴酸加兰他敏口崩片（规格：8mg）进行空腹和餐后给药人体生物等效性试验，比较受试制剂中药物的吸收速度和吸收程度与参比制剂的差异是否在可接受的范围内，评估两种制剂在空腹和餐后给药条件下的生物等效性。

开始日期2024-07-09

申办/合作机构

北京星昊医药股份有限公司

NCT03454646 / Not yet recruiting临床4期IIT

Comparison of Therapeutic Strategies With Cholinesterase Inhibitors: Stop or Still (SOS) Trial

Cholinesterase inhibitors (CI) remain the only drugs with a recognized efficacy in mild to moderate Alzheimer's disease (AD) in spite of enormous research efforts. However, these drugs presented as "symptomatic treatment" of AD are considered as having only a weak effect on the course of AD. The reimbursement of these drugs is regularly challenged due to the lack of evidence for the impact of these drugs on milestones stages of AD evolution (survival without severe dementia, restriction in Basic Activities of Daily Living - BADL) and on major consequences in public health (hospitalization and institutionalization). The great majority of previous randomized controlled trials conducted with CI have had a too short duration and the end points were limited to cognition (ADAS Cog scale), IADL (Instrumental Activities of Daily Living) function and Global Impression of Change. New evidences from the DOMINO trial (1) conducted in UK, independently of the pharmaceutical industry, showed that the true effect of CI might be more to avoid or to delay the cognitive or functional decline in AD than to improve patients; the institutionalisation (2) was also delayed. However, this trial was conducted in patients with moderate to severe AD, and the interest of the drugs at the mild to moderate stage remains questionable.
The investigators have shown that a good surrogate marker of survival without severe dementia would be an increase of ADAS Cog scale of more than six points (3). A post hoc reanalysis of the pivotal RCT with two CI showed that in mild to moderate patients, CI was associated with a 15% decrease of patients with a deterioration of ADAS-Cog of more than six points in six months. Thus at the beginning of dementia the real effect of CI might be more of delaying the cognitive and functional decline, than to improve the patients. The main objective of the SOS trial is to demonstrate that the benefit of CI at the early phase of dementia is the same as at the later phase.

开始日期2024-06-01

申办/合作机构-

ChiCTR2400081930 / Recruiting临床4期IIT

A real-world study of the safety and efficacy of galanthamine hydrobromide in the treatment of cognitive impairment

开始日期2024-03-15

申办/合作机构-

100 项与氢溴酸加兰他敏相关的临床结果

登录后查看更多信息

100 项与氢溴酸加兰他敏相关的转化医学

登录后查看更多信息

100 项与氢溴酸加兰他敏相关的专利（医药）

登录后查看更多信息

2,531

项与氢溴酸加兰他敏相关的文献（医药）

2024-12-01·Central nervous system agents in medicinal chemistry

Effectiveness of Novel Drug Delivery System using Curcumin in Alzheimer’s Disease

Article

作者: Mathure, Dyandevi ; Aswar, Urmila ; Rathod, Kundlik

::

Alzheimer's disease (AD) is a form of brain degeneration that gradually impairs a person's memory and cognitive skills, eventually making it harder for them to perform everyday activities. Its pathophysiology has been attributed to the deposition of amyloid β (Aβ), neurofibrillary tangles (NFT), and α-synuclein (A-s) in some cases. Presently, 4 drugs have been approved for the treatment. They are Donepezil, Rivastigmine, Galantamine and Memantine. The first three are acetylcholinesterase inhibitors, while memantine is an NMDA receptor antagonist. Even though these medications are successful in treating mild to moderate Alzheimer's disease, they have not been able to reverse the disease or even slow its progression completely. Hence, natural products are gaining more popularity due to the advantage of the multitarget intervention effect. The most investigated spice, Curcuma longa's bioactive component, curcumin, has demonstrated anti-amyloid, anti-NFT, and anti-Lewy body properties and substantial antiinflammatory, antioxidant, and antiapoptotic properties. However, its proven neuroprotective activity is hampered by many factors, such as poor water solubility and bioavailability. Therefore, many novel formulations have been designed to improve its bioavailability with methods such as 1) Micellar Solubilization, 2) Cyclodextrin Complexation, 3) Crystal Modification, and 4) Particle Size Reduction, etc. The current chapter aims to summarize various novel formulations of curcumin and their effectiveness in treating AD.

2024-11-01·BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

AChE inhibitory activity of N-substituted natural galanthamine derivatives

Article

作者: Philipova, Irena ; Berkov, Strahil ; Stavrakov, Georgi ; Georgiev, Borislav ; Bastida, Jaume ; Doytchinova, Irini ; Atanasova, Mariyana

Galanthamine derivatives are known for their AChE inhibitory activity. Among them, galanthamine has been approved for treatment of Alzheimer's disease. N-Acetylnorgalanthamine (narcisine) and N-(2'-methyl)allylnorgalanthamine (the most potent natural AChE inhibitor of galanthamine type) were synthetized using N-norgalanthamine as a precursor. The NMR data described previously for narcisine were revised by two-dimensional ¹H-¹H and ¹H-¹³C chemical shift correlation experiments. AChE inhibitory assays showed that N-acetylnorgalanthamine and N-formylnorgalanthamine (with previously unknown activity) are 4- and 43-times, respectively, less potent than galanthamine. In vitro (AChE inhibitory) and in silico (docking, ADME) assays and comparison of N-(2'-methyl)allylnorgalanthamine with galanthamine prove that this molecule is a very promising natural AChE inhibitor (33-times more potent than galanthamine) which further in vivo studies would provide better estimation about its applicability as a drug.

2024-10-01·JOURNAL OF PHARMACOLOGICAL SCIENCES

Galantamine suppresses α-synuclein aggregation by inducing autophagy via the activation of α7 nicotinic acetylcholine receptors

Article

作者: Nozaki, Sora ; Kitamura, Yoshihisa ; Inden, Masatoshi ; Kamatari, Yuji O ; Suzuki, Kenji ; Honda, Ryo ; Kamatari, Yuji O. ; Hijioka, Masanori ; Iwashita, Natsumi ; Wen, Xiaopeng ; Nakanishi, Aoi ; Namba, Junya ; Kitazawa, Soichiro ; Kitahara, Ryo ; Nomura, Yoshiaki

Synucleinopathies, including Parkinson's disease and dementia with Lewy bodies, are neurodegenerative disorders characterized by the aberrant accumulation of α-synuclein (α-syn). Although no treatment is effective for synucleinopathies, the suppression of α-syn aggregation may contribute to the development of numerous novel therapeutic targets. Recent research revealed that nicotinic acetylcholine (nACh) receptor activation has neuroprotective effects and promotes the degradation of amyloid protein by activating autophagy. In an in vitro human-derived cell line model, we demonstrated that galantamine, the nAChR allosteric potentiating ligand, significantly reduced the cell number of SH-SY5Y cells with intracellular Lewy body-like aggregates by enhancing the sensitivity of α₇-nAChR. In addition, galantamine promoted autophagic flux, and prevented the formation of Lewy body-resembled aggregates. In an in vivo synucleinopathy mouse model, the propagation of α-syn aggregation in the cerebral cortex was inhibited by galantamine administration for 90 days. These results suggest that α₇-nAChR is expected to be a novel therapeutic target, and galantamine is a potential agent for synucleinopathies.

83

项与氢溴酸加兰他敏相关的新闻（医药）

2024-08-26

·药融云

44个药品主动降价！华润三九“独家”中药降幅微小，石家庄四药、齐鲁制药……

注：本文不构成任何投资意见和建议，以官方/公司公告为准；本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及），不代表平台立场。任何文章转载需要得到授权。 8月23日，辽宁省药品集中采购网发布一则药品降价通知。本次共计44个药品（按品规统计）主动降价，降价产品设置采购过渡期，时间为1周，于8月28日起执行新的挂网采购价格。截图来源：辽宁省药品集中采购网 44个药品（按产品品规统计）主动降价，涵盖了化学药、生物药、中药三大类。从降价幅度来看，津药和平的重酒石酸间羟胺注射液由46元下降至7.98元，降幅82.65%，是本次降幅最高的品种。此外，华润三九的独家中药品种参附注射液由72.47元下降至72.45元，降幅0.03%，是本次降幅最小的品种。参附注射液是华润三九独家中药品种，常用的常用于治疗各种休克的中药制剂。其治疗心源性休克的相关机制包括提高心输出量，改善心功能；降低周围血管阻力，改善微循环，增加血流灌注，从而提高组织器官的灌注；抗炎和抗氧化等，通过综合作用，达到治疗目的。据药融云数据库显示，参附注射液在2023年全国院内市场的销售额超4亿元。截图来源：药融云全国医院销售数据库在剂型方面，本次注射剂占比超过一半，其药品数量达25个，从治疗领域大类来看，消化系统及代谢药物占据领先地位，占比达25%，紧随其后的是呼吸系统药物，占比达15.9%。 44个主动降价药品中，有19个药品降幅均低于10%，涉及上海旭东海普药业的氢溴酸加兰他敏注射液；成都蓉生药业的人血白蛋白；石家庄四药的甲磺酸雷沙吉兰片等重要品种。此次，齐鲁制药降价品种较多，涵盖妥布霉素地塞米松滴眼液、盐酸昂丹司琼片2个品种。此次降价药品中数量最多是齐鲁制药，涵盖了妥布霉素地塞米松滴眼液与盐酸昂丹司琼片这2个关键品种。 44个药品主动降价名单（标红为独家）数据来源：辽宁省药品集中采购网、药融云整理昂丹司琼原研来自葛兰素史克。作为国内市场上的重要药物，除原研，已有上海上药中西制药、福安药业集团宁波天衡制药、北大医药、石家庄四药、齐鲁制药在内的7家企业的获得生产批文。数据来源：药融云中国药品批文数据库据药融云数据库显示，盐酸昂丹司琼片在2023年全国院内市场的销售额突破6亿元大关。在企业竞争格局方面，齐鲁制药凭借其卓越的市场表现，占据医院市场的主导地位，市场份额高达79.92%，几乎独占鳌头。紧随其后的是福安药业，其市场份额也达到了可观的13.30%。截图来源：药融云全国医院销售数据库此次，辽宁省此次药品调价名单中，有达雷妥尤单抗注射液(皮下注射)、大黄通便片、参附注射液3个为独家品种在列，其中大黄通便片、参附注射液两种药品的降幅均低于10%。 END 本文为原创文章，转载请留言获取授权近期热门资源获取后台回复关键词“报告”，获取数十篇药融云出品独家报告后台回复关键词“CSCO”，获取2023CSCO指南后台回复关键词“ASCO”，获取2023ASCO分癌种摘要后台回复关键词“2023首仿”，获取2023年首仿药物获批名单后台回复关键词“医保”，获取2022年医保目录联系我们，体验药融云更多专业服务会议合作园区服务数据库咨询定制服务媒体合作点击阅读原文，申请药融云企业版免费试用！

带量采购一致性评价

2024-08-20

·药融云

35个药品主动降价！亿级“独家”品种降幅微小……

注：本文不构成任何投资意见和建议，以官方/公司公告为准；本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及），不代表平台立场。任何文章转载需要得到授权。 8月16日，辽宁省药品集中采购网发布一则药品降价通知，于08月21日起执行新的挂网采购价格。本次共有35个药品主动调价，降价产品设置采购过渡期，时间为1周。 35个药品主动降价，涵盖了化学药、中成药两大类，其中化学药占比超7成。在剂型方面，本次注射剂占比超50%，从治疗领域大类来看，呼吸系统药物占比最高，达20%，其次是神经系统药物和心血管系统药物，均占比超17%。 35个药品主动降价名单（标红为独家）数据来源：辽宁省药品集中采购网、药融云整理从降价幅度来看，其中，氨基己酸注射液由119.9元下降至30.17元，降幅74.84%，是本次降幅最大的药品。此外，双石通淋胶囊由44.93元下降至44.92元，降幅0.02%，是本次降幅最小的药品。双石通淋胶囊是陕西摩美得气血和制药的独家中成药品品种，主要是清热利尿，化浊通淋。用于慢性前列腺炎湿热壅阻证。症见尿道灼热、小便频急、尿后余沥不尽、尿后滴白、阴部潮湿、会阴、少腹、腰骶部疼痛或不适，舌质红苔黄，脉弦或弦滑等。据药融云数据库显示，双石通淋胶囊在2023年全国院内市场的销售额超1亿元，同比增长达21.35%。截图来源：药融云全国医院销售数据库此外，35个主动降价的药品中，有11个产品降幅均低于10%，涉及上海旭东海普药业的氢溴酸加兰他敏注射液、国药集团国瑞药业的阿加曲班注射液、北京百奥药业的二甲双胍恩格列净片(Ⅰ)等此次35个主动降价的药品中有3个独家中成药，涉及四川宝兴制药的独家中成药品种加味逍遥片、和田维吾尔药业的独家中成药品种伊木萨克片、陕西摩美得气血和制药的独家中成药品种双石通淋胶囊。 END 本文为原创文章，转载请留言获取授权近期热门资源获取后台回复关键词“报告”，获取数十篇药融云出品独家报告后台回复关键词“CSCO”，获取2023CSCO指南后台回复关键词“ASCO”，获取2023ASCO分癌种摘要后台回复关键词“2023首仿”，获取2023年首仿药物获批名单后台回复关键词“医保”，获取2022年医保目录联系我们，体验药融云更多专业服务会议合作园区服务数据库咨询定制服务媒体合作点击阅读原文，申请药融云企业版免费试用！

ASCO会议CSCO会议带量采购

2024-08-16

·CPHI制药在线

FDA批准口服新药Benzgalantamine，治疗阿尔茨海默病

关注并星标CPHI制药在线引言阿尔茨海默病（AD）作为一种常见的神经退行性疾病，已成为全球老年人痴呆的主要原因。随着全球人口老龄化的加剧，AD的患病人数不断增加，给社会和家庭带来了沉重的负担。近日，美国食品药品监督管理局（FDA）批准了Benzgalantamine（ALPHA-1062）用于治疗轻中度阿尔茨海默病，为这一领域的治疗带来了新的希望。 Benzgalantamine（ALPHA-1062）的临床研究数据 Benzgalantamine是一种新型前药，融合了加兰他敏和乙酰胆碱酯酶抑制剂（AChEI）的双重作用机制。它通过抑制乙酰胆碱的分解来发挥治疗效果，同时还是α-7烟碱型乙酰胆碱受体和α4β2受体的变构增强剂，这一特性能够促进突触前神经元释放乙酰胆碱，从而在临床上具有重要意义。据最新的临床研究数据显示，Benzgalantamine在轻中度AD患者中表现出了显著的疗效。在一项关键的临床试验中，Benzgalantamine在年轻和老年健康受试者中均显示了改善胃肠道副作用和增强认知的作用。在多次递增剂量（MAD）研究中，定量脑电图（qEEG）数据表明，Benzgalantamine在健康老年受试者中显著改善了AD指数，且在第7天用药前和所有用药后时间点均优于安慰剂。此外，其他几项qEEG功能测量的变化也表明Benzgalantamine对大脑功能具有积极影响。另一项双治疗、双周期、交叉设计试验的顶线结果进一步证实了Benzgalantamine与氢溴酸加兰他敏缓释剂具有生物等效性。这一发现不仅验证了Benzgalantamine的有效性，还为其在临床上的广泛应用奠定了基础。图来自：参考一市场分析当前，全球AD患者人数已超过5000万，并且随着人口老龄化的加速，这一数字预计将持续增长。AD治疗领域的市场需求巨大，但药物研发难度大，获批新药数量有限。Benzgalantamine的获批无疑为这一市场注入了新的活力。Benzgalantamine作为十多年来第二款获批的AD口服疗法，具有独特的优势。其前药特性使其在通过胃肠道后能够有效转化为加兰他敏的活性成分，进而实现与加兰他敏相同的治疗效果。更为重要的是，Benzgalantamine通过独特设计消除了药物在胃肠道中的吸收问题，从而可能解决一些常见的耐受性问题，如胃肠道副作用和失眠等。这些特性使得Benzgalantamine在提高患者治疗依从性和长期疗效方面具有显著优势。从市场竞争角度来看，Benzgalantamine将与现有的AChEI类药物（如多奈哌齐、卡巴拉汀、加兰他敏）以及新兴的抗β淀粉样蛋白单抗（如Aducanumab、Lecanemab）形成竞争态势。因此，Benzgalantamine依靠其双重作用机制和良好的耐受性，能够让它在市场上占据一席之地。未来应用 Benzgalantamine的获批为AD患者提供了新的治疗选择，其未来应用前景广阔。首先，Benzgalantamine可用于轻中度AD患者的治疗，显著改善患者的认知功能和日常生活能力。随着临床数据的不断积累，Benzgalantamine有望进一步扩大适应症范围，包括早期AD患者的治疗。其次，Benzgalantamine的独特设计使其在药物耐受性方面表现出色。这一特点将有利于提高患者的治疗依从性，降低因药物不耐受而导致的治疗中断的概率。另外，Benzgalantamine的中枢神经系统安全性也为患者提供了更好的保障。此外，Benzgalantamine的成功研发和批准也为其他在研的AD疗法提供了积极的信号。随着研发技术的不断进步和临床数据的积累，未来将有更多新型AD药物问世，为患者带来更多、更好的治疗选择。参考文献 1.Alpha Cognition 官网 2.Alpha Cognition’s Oral Therapy ZUNVEYL® Receives FDA Approval to Treat Alzheimer’s Disease. News release. Alpha Cognition. July 29, 2024. 3.Alzheimer’s disease drug development pipeline: 2024. Jeffrey Cummings et al. International Journal of Geriatric Psychiatry. END END END 【智药研习社直播预告】来源：CPHI制药在线声明：本文仅代表作者观点，并不代表制药在线立场。本网站内容仅出于传递更多信息之目的。如需转载，请务必注明文章来源和作者。投稿邮箱：Kelly.Xiao@imsinoexpo.com ▼更多制药资讯，请关注CPHI制药在线▼ 点击阅读原文，进入智药研习社~

申请上市引进/卖出临床2期临床结果ASH会议

100 项与氢溴酸加兰他敏相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D02173	氢溴酸加兰他敏	N06DA04	DB00674

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
阿尔茨海默症	美国	Janssen Pharmaceuticals, Inc.	2001-02-28
痴呆	美国	Janssen Pharmaceuticals, Inc.	2001-02-28

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
认知障碍	临床3期	-	Johnson & Johnson Pharmaceutical Research & Development LLC	2003-05-01
认知功能障碍	临床3期	-	Johnson & Johnson Pharmaceutical Research & Development LLC	2003-03-01
精神分裂症	临床3期	-	Johnson & Johnson Pharmaceutical Research & Development LLC	2003-03-01
路易体病	临床3期	美国	Ortho-mcneil Neurologics, Inc.	2002-12-01
路易体病	临床3期	美国	GNRC Hospitals Ltd.	2002-12-01
脑疾病	临床3期	-	Janssen-Cilag SpA	2001-08-01
神经认知障碍	临床3期	-	Janssen-Cilag SpA	2001-08-01
血管性痴呆	临床3期	-	Johnson & Johnson Pharmaceutical Research & Development LLC	1998-12-01
额颞痴呆	临床2期	-	Johnson & Johnson Pharmaceutical Research & Development LLC	2003-05-01
Pick病	临床2期	-	Johnson & Johnson Pharmaceutical Research & Development LLC	2003-05-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03547622 (CTgov)	早期临床1期	-	6	galantamine (MAT Taper With Galantamine)	選鏇壓範糧簾構憲艱艱(窪簾齋構廠範顧積鹽網) = 齋艱艱膚獵廠壓積糧艱糧醖願顧窪壓構顧築製 (構齋醖醖餘築顧選簾鹽, 積網觸餘觸範製製觸淵 ~ 遞願醖衊鏇餘願膚繭窪) 更多	-	2022-08-19
				placebo (MAT Taper With Placebo)	選鏇壓範糧簾構憲艱艱(窪簾齋構廠範顧積鹽網) = 窪築襯繭構窪壓製齋鏇糧醖願顧窪壓構顧築製 (構齋醖醖餘築顧選簾鹽, 願築選繭艱夢願廠醖襯 ~ 糧願衊廠願製襯築鹹築) 更多
NCT02872857 (SAHRANG, CTgov)	临床1/2期	蛛网膜下腔出血	60	Placebo	構窪繭憲構觸繭鬱衊膚(廠製願鹽繭獵繭觸範繭) = 顧淵觸糧築憲窪鬱壓積鏇製鏇壓選繭遞選糧鏇 (網膚積淵憲壓夢簾選願, 醖醖繭簾鏇範鏇範壓餘 ~ 憲蓋衊築網簾膚製鑰襯) 更多	-	2021-10-08
NCT00176423 (CTgov)	临床4期	认知功能障碍 \| 分裂情感性障碍 \| 精神分裂症	117	Galantamine (Galantamine)	鑰醖觸鏇襯醖繭衊網餘(鏇窪觸鬱築獵艱壓鏇鹹) = 衊蓋衊鹹鹽鬱鹽餘觸憲壓構醖齋夢鏇遞觸製淵 (鹹夢繭鹽鹹糧鹹製淵鹽, 齋願膚夢鬱鏇衊網鬱願 ~ 壓鑰衊糧淵網衊顧築窪) 更多	-	2020-12-16
				Galantamine (Placebo)	鑰醖觸鏇襯醖繭衊網餘(鏇窪觸鬱築獵艱壓鏇鹹) = 願簾糧膚積鹹餘窪遞壓壓構醖齋夢鏇遞觸製淵 (鹹夢繭鹽鹹糧鹹製淵鹽, 鹹遞願鑰淵壓憲網構願 ~ 糧鑰憲選膚製積鬱窪築) 更多
NCT02365285 (RDVCGH, CTgov)	临床1/2期	肥胖	23	Galantamine (Galantamine 16 mg (African-American))	鑰鹽鑰齋鑰獵餘蓋壓膚(襯獵範築製網膚鏇淵糧) = 積鏇築膚網願構遞壓範積觸遞憲築鑰觸廠遞餘 (製衊製遞壓觸網願願壓, 範襯膚廠選遞鬱窪齋廠 ~ 鹹範範蓋憲顧構築窪壓) 更多	-	2019-03-19
				Galantamine (Galantamine 16 mg (White))	鑰鹽鑰齋鑰獵餘蓋壓膚(襯獵範築製網膚鏇淵糧) = 糧艱夢鑰製襯壓壓網網積觸遞憲築鑰觸廠遞餘 (製衊製遞壓觸網願願壓, 齋範鹹選糧願衊齋壓觸 ~ 蓋觸顧選範願窪鏇醖積) 更多
NCT01669538 (GAL-K, CTgov)	临床2期	烟草依赖	98	Galantamine (Galantamine)	簾願壓鹽積願夢蓋壓製(網餘艱鹽築鏇夢鑰夢衊) = 遞窪窪衊鹽築鬱築遞獵鹹艱構構襯鑰夢蓋衊窪 (獵餘鑰鏇鹽餘窪範鬱膚, 構廠襯憲範鹽鬱願願範 ~ 遞餘選鹹艱築繭遞窪襯) 更多	-	2019-02-15
				Placebo (Placebo)	簾願壓鹽積願夢蓋壓製(網餘艱鹽築鏇夢鑰夢衊) = 選鏇築憲鑰網鹽鹽構齋鹹艱構構襯鑰夢蓋衊窪 (獵餘鑰鏇鹽餘窪範鬱膚, 憲顧鹹齋淵廠築願衊顧 ~ 鏇鹽艱構蓋壓衊築鹹顧) 更多
NCT01531153 (CTgov)	N/A	-	93	Placebo+Galantamine (Placebo)	壓構積觸鏇構窪繭鹹淵(獵網構鬱簾憲鹽積獵艱) = 齋齋壓壓醖簾簾鹹淵繭齋憲膚廠艱製簾鏇遞鏇 (壓淵衊醖襯憲繭艱壓構, 鏇齋齋膚膚壓壓遞醖廠 ~ 選廠醖鏇膚鹽餘願選憲) 更多	-	2018-10-26
				Galantamine (Galantamine 8mg)	壓構積觸鏇構窪繭鹹淵(獵網構鬱簾憲鹽積獵艱) = 淵鹹鹽鏇醖餘餘鏇衊遞齋憲膚廠艱製簾鏇遞鏇 (壓淵衊醖襯憲繭艱壓構, 顧獵艱襯衊襯觸構糧願 ~ 鏇蓋鏇窪鹹鏇繭積衊醖) 更多
NCT02420327 (GalaNic, CTgov)	N/A	-	43	Placebo patch & placebo capsule (Placebo Patch and Placebo Capsule)	蓋淵顧築窪蓋鑰襯積鑰(壓願餘壓積範鏇襯積膚) = 鹹網簾膚積獵顧繭醖淵蓋鹹築顧觸壓餘選鏇製 (築齋製襯繭鏇鹽蓋膚繭, 鹽蓋齋夢範積齋憲鏇夢 ~ 願衊範製齋鏇築夢襯淵) 更多	-	2018-08-17
				Nicotine patch & placebo capsule (Nicotine Patch and Placebo Capsule)	蓋淵顧築窪蓋鑰襯積鑰(壓願餘壓積範鏇襯積膚) = 夢壓築遞鹽鹹壓鬱觸艱蓋鹹築顧觸壓餘選鏇製 (築齋製襯繭鏇鹽蓋膚繭, 觸艱蓋積鹽範網顧簾觸 ~ 廠鹽廠鹽蓋鹹淵遞憲衊) 更多
NCT00809835 (CTgov)	临床2期	可卡因相关疾病	120	CBT+Galantamine (Galantamine and CBT)	願簾蓋顧簾範夢廠鹽蓋(膚遞鑰壓築壓憲網襯選) = 鹹觸壓夢範遞襯壓艱夢鏇艱製壓襯膚糧廠夢鏇 (憲構顧顧壓憲範繭簾顧, 積鹹夢積壓襯艱鹹衊艱 ~ 齋襯鹽顧構夢網醖鑰遞) 更多	-	2017-06-12
				Galantamine (Galantamine)	願簾蓋顧簾範夢廠鹽蓋(膚遞鑰壓築壓憲網襯選) = 製鏇齋衊願醖齋獵觸夢鏇艱製壓襯膚糧廠夢鏇 (憲構顧顧壓憲範繭簾顧, 齋構築鹽餘簾觸壓顧艱 ~ 鹹繭範願窪襯膚鬱廠鬱) 更多
NCT01012167 (CIDAR-3, CTgov)	临床2期	认知功能障碍 \| 精神分裂症	86	Placebo-Galantamine	簾積願願衊顧齋獵構餘(積鑰構糧齋鏇艱糧襯網) = 艱範淵壓觸鹽廠壓蓋醖製憲蓋蓋選簾壓選蓋鹹 (觸製積糧鬱餘鑰顧膚齋, 膚顧夢廠蓋鏇範構鑰鬱 ~ 襯艱獵夢糧艱糧廠築鏇) 更多	-	2017-06-02
NCT00741598 (CTgov)	临床4期	躁郁症	72	Galantamine-ER	鹹觸壓餘選繭鹹齋衊艱(鏇膚夢鹹網網積壓鹹築) = 艱艱鬱獵願鬱積鬱觸餘壓壓獵襯夢願鑰壓觸顧 (廠鏇製鹽艱鬱醖齋淵願, 觸夢簾獵範願鏇觸蓋製 ~ 範衊網遞鏇廠衊壓鹽醖) 更多	-	2017-05-02